| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Alternative Names | (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine, methanesulfonate; TVP-1012; Azilect |
| Cas No. | |
| Form | White crystalline powder |
| Molecular Weight | |
| Product Type | |
| Purity | |
| Shipping | |
| SMILES | |
| Solubility | May be dissolved in DMSO (50 mg/ml); or water (50 mg/ml); Ethanol (30 mg/ml) |
| Source | Synthetic |
| Storage |
MAO-B inhibitor used in Parkinson’s disease. Enhances dopaminergic signaling, prevents α-synuclein toxicity, restores TrkB signaling, and increases BDNF levels.
GHS Classification: GHS07 Acute Toxicity (Category 4), Skin Irritant (Category 2), Eye Irritant (Category 2), Specific Target Organ Toxicity (Category 3); Hazard Statement: H302 Harmful if Swallowed
Rasagiline mesylate (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-577)
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close
equivalents, or discuss custom synthesis with the right QC documentation (RUO).
2. E Cereda et al. J. Neurol. 2017 264:1254
3. A Cronin and M Grealy Neuroscience 2017 367:34
4. SS Kang et al. Proc. Natl. Acad. Sci. USA 2017 114:10773
5. A Ledreux et al. Brain Res. 2016 1631:34
